- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07720206
Abnormality of the Central Canal of the Spinal Cord in Syringomyelia in a Patient With a Basal Skull Malformation (SYRCANAL)
The aim of this study is to analyze the association between a deformity of the cranial portion of the central spinal canal and syringomyelia in patients with a Chiari-type malformation of the craniocervical junction.
The investigators hypothesize that Chiari malformation, defined by the herniation of the cerebellar tonsils through the foramen magnum, may be responsible for a deformation of the cranial portion of the central spinal canal, and that this deformation is associated with the presence of syringomyelia in patients with this malformation.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Chiari Malformation Type I (CM-I) is a congenital anomaly characterized by downward displacement of the cerebellar tonsils through the foramen magnum, which may disrupt cerebrospinal fluid (CSF) circulation at the craniovertebral junction. The condition generally results from underdevelopment of the posterior cranial fossa, leading to insufficient space for the cerebellum. This anatomical abnormality can cause a wide range of heterogeneous symptoms, including occipital headaches triggered by coughing or exertion, neck pain, dizziness, balance disturbances, paresthesia, limb weakness, and swallowing difficulties.
One of the most concerning complications is syringomyelia/hydromyelia, which corresponds to the development of fluid-filled cavities within the spinal cord. These cavities may either be adjacent to the central canal (syringomyelia) or result from dilation of the central canal itself (hydromyelia). Associated spinal cord involvement may lead to specific neurological symptoms and is often a major indication for surgical treatment of Chiari malformation.
The decision to perform surgical decompression of the craniovertebral junction must balance the potential benefits against the associated risks. Furthermore, surgical outcomes remain variable and sometimes uncertain. Some symptoms may persist despite surgery, and syringomyelia regression is inconsistent. A better understanding of the pathophysiology of syringomyelia associated with Chiari malformation is therefore essential to improve patient selection and optimize surgical strategies.
Although the pathophysiology of syringomyelia in Chiari malformation has been investigated in several studies, it remains only partially understood. Recently, the position of the obex has been suggested to be associated with the presence of syringomyelia in patients with Chiari malformation. The obex is the neurological structure located at the cranial end of the central canal. Based on previous findings, investigators hypothesize that a low-lying obex may induce deformation of the central canal, creating a folding or kinking effect that could explain downstream canal dilation. Our primary hypothesis is therefore that the morphology of the central canal at the cervicomedullary junction (including angulation, folding, or compression) is a key factor influencing the presence or absence of associated hydromyelia/syringomyelia and, consequently, clinical severity.
Animal studies support a pathophysiological cascade involving initial mechanical deformation of the central canal followed by pericanal inflammation contributing to syringomyelia formation. According to this novel hypothesis, cerebellar tonsillar descent without associated central canal deformation would confer a lower risk of syringomyelia and unfavorable clinical progression than cases involving deformation of the cranial portion of the central canal.
In vivo visualization and morphological assessment of the cranial portion of the ependymal central canal using MRI therefore offer the potential to identify new risk markers for Chiari malformation that may ultimately assist surgical decision-making. However, when the canal is not dilated, visualization remains challenging, as does the identification of potential pericanal inflammation.
Several years ago, Tourdias et al. developed a specific MRI sequence known as White Matter-nulled (WMn) MPRAGE, which enhances contrast between structures of the central nervous system, including the thalamus, thereby improving the accuracy of thalamic assessment in pathological conditions. More recently, this group demonstrated that the WMn-MPRAGE sequence can be adapted for spinal cord imaging, maximizing the detection of spinal cord lesions. In collaboration with the Anatomy Laboratory of the University of Bordeaux, it was demonstrated that WMn-MPRAGE enables reliable visualization of the spinal cord central canal in healthy subjects when compared with previous anatomical specimen studies. Furthermore, recent advances in spinal cord diffusion MRI, particularly through artificial intelligence-based denoising methods, now enable detailed assessment of spinal cord microstructure and may allow quantification of biomarkers associated with pericanal inflammation.
Thus, the pathophysiology of Chiari Malformation Type I remains incompletely understood. Investigators hypothesize that analysis of the morphology of the cranial portion of the ependymal central canal using WMn-MPRAGE imaging, combined with assessment of the adjacent spinal cord microstructure, may provide novel biomarkers of associated syringomyelia risk and clinical severity.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jean-Rodolphe VIGNES, Pr
- Número de telefone: +33 05 57 95 54 43
- E-mail: jean-rodolphe.vignes@chu-bordeaux.fr
Estude backup de contato
- Nome: Paul ROBLOT, Dr
- Número de telefone: +33 05 56 79 55 43
- E-mail: paul.roblot@chu-bordeaux.fr
Locais de estudo
-
-
-
Bordeaux, França
- Bordeaux University Hospital
-
Contato:
- Jean-Rodolphe VIGNES, PR
- Número de telefone: +33 05 56 79 55 43
- E-mail: jean-rodolphe.vignes@chu-bordeaux.fr
-
Investigador principal:
- Jean-Rodolphe VIGNES, Pr
-
Subinvestigador:
- Paul ROBLOT, Dr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adult patients being treated for Chiari malformation or syringomyelia at Bordeaux University Hospital
- Patients admitted for an initial surgical consultation regarding Chiari malformation with or without syringomyelia at Bordeaux University Hospital
- Individuals enrolled in or covered by a social security program.
- Free, informed, and express consent (confirmed in writing) (no later than the day of enrollment and prior to any examination required by the study).
Exclusion Criteria:
- Pregnant or breastfeeding patients
- Contraindications to MRI
- Individuals deprived of their liberty by judicial or administrative order,
- Adults subject to legal protective measures (guardianship, conservatorship, judicial protection).
- Patients who have previously undergone surgery for a Chiari malformation or a posterior fossa malformation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Patients with Chiari malformation with associated syringomyelia
|
Magnetic Resonance Imaging (MRI) using T1, T2, White-Matter nulled (WMn), and diffusion sequences
|
|
Experimental: Patients with Chiari malformation without associated syringomyelia
|
Magnetic Resonance Imaging (MRI) using T1, T2, White-Matter nulled (WMn), and diffusion sequences
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Deformation of the central canal of the spinal cord
Prazo: At inclusion (D0)
|
The central canal deformation index of the spinal cord, calculated based on the angle of the curves and the length of each segment between two curves.
|
At inclusion (D0)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Protrusion of the cerebellar tonsils
Prazo: at inclusion (day 0)
|
Protrusion of the cerebellar tonsils into the foramen magnum on T2-weighted MRI. Commonly accepted definition of Chiari malformation Type I: cerebellar tonsils extending more than 5 mm below the McRae line on MRI. The McRae line is defined as the anatomical line connecting the basion and the opisthion, corresponding to the anterior and posterior margins of the foramen magnum. |
at inclusion (day 0)
|
|
Presence and dimensions of syringomyelia
Prazo: At inclusion (day 0)
|
The presence and dimensions of syringomyelia on MRI using T2 and WMn-MPRAGE sequences
|
At inclusion (day 0)
|
|
Distance between the obex and the foramen magnum
Prazo: At inclusion (Day 0)
|
Distance between the obex and the foramen magnum on T2-weighted and WMn-MPRAGE MRI sequences
|
At inclusion (Day 0)
|
|
Diffusion MRI parameter (1)
Prazo: At inclusion (Day 0)
|
Diffusion MRI parameter (mean diffusivity) in the pericanalicular region
|
At inclusion (Day 0)
|
|
Diffusion MRI parameter (2)
Prazo: At inclusion (Day 0)
|
Diffusion MRI (anisotropy fraction) in the pericanalicular region
|
At inclusion (Day 0)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CHUBX 2026/003
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em MRI
-
Rennes University HospitalBayerRescindidoEsclerose Múltipla (EM) | Doença InflamatóriaFrança
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupDesconhecidoCâncer de mama | BIRADS 3 | BIRADS 4 | BIRADS 5Estados Unidos
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)RescindidoOsteossarcoma | Sarcoma de Ewing | Doença de PagetEstados Unidos
-
Seoul National University Bundang HospitalBayerConcluídoTraumaRepublica da Coréia
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)Ativo, não recrutandoCâncer de Cabeça e PescoçoEstados Unidos
-
Chang Gung Memorial HospitalRecrutamentoCâncer de próstata | Imagem de ressonância magnética | Teste controlado e aleatórioTaiwan
-
Mohamed Ibrahim AbbasDesconhecidoLesão Vertebral
-
Reto Sutter, MDRecrutamentoImagem de ressonância magnéticaSuíça
-
Five Eleven Pharma, Inc.Indiana UniversityRecrutamento
-
Mario Negri Institute for Pharmacological ResearchAinda não está recrutandoDoença renal diabética (DRD)Itália